CO2018010504A2 - Inhibidores del enlace proteína-proteína de wdr5 - Google Patents

Inhibidores del enlace proteína-proteína de wdr5

Info

Publication number
CO2018010504A2
CO2018010504A2 CONC2018/0010504A CO2018010504A CO2018010504A2 CO 2018010504 A2 CO2018010504 A2 CO 2018010504A2 CO 2018010504 A CO2018010504 A CO 2018010504A CO 2018010504 A2 CO2018010504 A2 CO 2018010504A2
Authority
CO
Colombia
Prior art keywords
protein
wdr5
binding inhibitors
compounds
protein binding
Prior art date
Application number
CONC2018/0010504A
Other languages
English (en)
Spanish (es)
Inventor
Rima Al-Awar
Carlos Armando Zepeda-Velazquez
Gennady Poda
Methvin Isaac
David Uehling
Brian Wilson
Babu Joseph
Yong Liu
Pandiaraju Subramanian
Ahmed Mamai
Michael Prakesch
Julia Kathleen Stille
Original Assignee
Propellon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propellon Therapeutics Inc filed Critical Propellon Therapeutics Inc
Publication of CO2018010504A2 publication Critical patent/CO2018010504A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CONC2018/0010504A 2016-03-01 2018-09-28 Inhibidores del enlace proteína-proteína de wdr5 CO2018010504A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662301673P 2016-03-01 2016-03-01
PCT/CA2017/050269 WO2017147700A1 (en) 2016-03-01 2017-03-01 Inhibitors of wdr5 protein-protein binding

Publications (1)

Publication Number Publication Date
CO2018010504A2 true CO2018010504A2 (es) 2018-12-14

Family

ID=59743306

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0010504A CO2018010504A2 (es) 2016-03-01 2018-09-28 Inhibidores del enlace proteína-proteína de wdr5

Country Status (17)

Country Link
US (2) US11319299B2 (enExample)
EP (1) EP3423451B1 (enExample)
JP (3) JP7624690B2 (enExample)
KR (1) KR20180120720A (enExample)
CN (1) CN109195965B (enExample)
AU (1) AU2017226004B2 (enExample)
BR (1) BR112018067392A2 (enExample)
CA (1) CA3015406A1 (enExample)
CL (1) CL2018002505A1 (enExample)
CO (1) CO2018010504A2 (enExample)
DK (1) DK3423451T3 (enExample)
EA (1) EA038109B1 (enExample)
EC (1) ECSP18073726A (enExample)
IL (1) IL261472B (enExample)
MX (1) MX2018010374A (enExample)
WO (1) WO2017147700A1 (enExample)
ZA (1) ZA201805879B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319299B2 (en) * 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
AU2017226005A1 (en) 2016-03-01 2018-09-06 Propellon Therapeutics Inc. Inhibitors of WDR5 protein-protein binding
MX2019004950A (es) 2016-10-28 2019-09-26 Icahn School Med Mount Sinai Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
CA3045037A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
CN117105827A (zh) 2017-03-27 2023-11-24 魁北克电力公司 用于电解质组合物中或用作电极添加剂的盐
JP2020532561A (ja) * 2017-09-06 2020-11-12 プロペロン セラピューティクス インコーポレイテッド Ｗｄｒ５タンパク質−タンパク質結合の阻害剤
US10501466B2 (en) 2017-09-19 2019-12-10 Vanderbilt University WDR5 inhibitors and modulators
CN111566086B (zh) * 2018-01-04 2023-08-01 北京大学深圳研究生院 同时抑制lsd1和hdac靶点的化合物及其应用
JP2021515013A (ja) 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
CN108715585A (zh) 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
US10844044B2 (en) 2018-06-14 2020-11-24 Vanderbilt University WDR5 inhibitors and modulators
JP2021527666A (ja) * 2018-06-21 2021-10-14 アイカーン スクール オブ メディスン アット マウント シナイ Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
WO2020010204A1 (en) 2018-07-05 2020-01-09 Icahn School Of Medicine At Mount Sinai Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
US10807959B2 (en) 2018-08-16 2020-10-20 Vanderbilt University WDR5-MLL1 inhibitors and modulators
CN109734674B (zh) 2019-02-26 2022-08-26 中国药科大学 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
US12240855B2 (en) 2019-03-06 2025-03-04 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative
CN114423463B (zh) 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
CN111039860B (zh) * 2019-12-02 2022-09-13 河北科技大学 2-羟基-n-(4’-氯联苯-2-基)烟酰胺的合成方法及应用
CN113024538B (zh) * 2019-12-24 2022-09-09 南开大学 吡唑酰胺类化合物及其制备和在防治植物病菌病和杀虫中的应用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CN114539073A (zh) * 2022-02-18 2022-05-27 郑州萃智医药科技有限公司 3-溴-2-氯-4,6-二氟苯胺的合成方法
CA3245868A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc PHENYL TRIAZOLE PROTEIN-PROTEIN INTERACTION INHIBITOR MLL1-WDR5
CA3245866A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
US20230286948A1 (en) * 2022-03-14 2023-09-14 Huyabio International, Llc Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor
AR129265A1 (es) 2022-05-12 2024-08-07 Syngenta Crop Protection Ag Compuestos de alcoxi-heteroaril-carboxamida o tioamida
CN119365449A (zh) * 2022-07-01 2025-01-24 甘李药业股份有限公司 一种用作wdr5抑制剂的化合物或其可药用盐及其应用
WO2024015478A2 (en) * 2022-07-14 2024-01-18 Huyabio International, Llc Combination therapies of wdr5 inhibitors and pd-1 inhibitors
CN115974965B (zh) * 2022-08-31 2025-09-12 中国科学技术大学 一种靶向wdr5的多肽抑制剂及其用途
TW202619730A (zh) 2024-09-13 2026-05-16 日商亞力維克希斯股份有限公司 Wdr5抑制劑、化合物、醫藥組合物、及其使用方法
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用
CN119661474B (zh) * 2024-12-16 2026-05-29 中国药科大学 一类羟肟酸类的双靶点化合物衍生物及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728130A1 (en) 1993-11-12 1996-08-28 PHARMACIA &amp; UPJOHN COMPANY Pyrimidine-thioalkyl and alkylether compounds
JPH0959236A (ja) 1995-08-23 1997-03-04 Dai Ichi Seiyaku Co Ltd ベンズアミド化合物
US20010051719A1 (en) 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｂａｃｅのインヒビター
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1542699A4 (en) 2002-07-15 2009-03-25 Myriad Genetics Inc COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
GB0412072D0 (en) 2004-05-28 2004-06-30 Syngenta Participations Ag Chemical compounds
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
KR100919905B1 (ko) 2005-01-26 2009-10-06 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
KR20080092412A (ko) 2006-02-06 2008-10-15 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
RU2452492C2 (ru) 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
CN101679266B (zh) * 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
BRPI0813356A2 (pt) 2007-06-15 2014-12-30 Irm Llc Inibidores de proteína quinase e métodos para uso dos mesmos
CN101875617B (zh) 2009-03-23 2015-05-20 中国医学科学院药物研究所 烷氧基取代芳环的氨甲酰基类芳酸化合物及其制法和用途
EA201190235A1 (ru) 2009-05-07 2012-05-30 Астразенека Аб Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
CN107441097A (zh) 2010-04-16 2017-12-08 阿西纳斯公司 用于预防和治疗癌症的组合物以及方法
EP2627650A2 (en) * 2010-05-26 2013-08-21 Merck Sharp & Dohme Corp. N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
WO2011156557A2 (en) 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor
WO2011159685A2 (en) 2010-06-16 2011-12-22 The Regents Of The University Of Michigan Inhibition of wdr5 interaction with its binding partners and therapeutic methods
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
AR091586A1 (es) 2012-06-28 2015-02-11 Fujifilm Corp Derivado de amida o su sal como inhibidor de la produccion de colageno
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
EP2907802B1 (en) 2012-10-12 2019-08-07 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
EP3495359A1 (en) 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap modulators
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CN104926801B (zh) 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN105585565B (zh) 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN105837575B (zh) 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
CN105175284B (zh) * 2015-07-21 2017-06-16 中国药科大学 酰胺类化合物、制备方法及其医药用途
AU2017226005A1 (en) 2016-03-01 2018-09-06 Propellon Therapeutics Inc. Inhibitors of WDR5 protein-protein binding
PE20181583A1 (es) 2016-03-01 2018-10-04 Immatics Biotechnologies Gmbh Peptido recombinante derivado de la proteina duoxa2
US11319299B2 (en) 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
US10160763B2 (en) 2016-09-13 2018-12-25 Vanderbilt University WDR5 inhibitors and modulators
JP2020532561A (ja) 2017-09-06 2020-11-12 プロペロン セラピューティクス インコーポレイテッド Ｗｄｒ５タンパク質−タンパク質結合の阻害剤
US10501466B2 (en) 2017-09-19 2019-12-10 Vanderbilt University WDR5 inhibitors and modulators
EP3870173A4 (en) 2018-10-24 2022-06-22 Vanderbilt University WDR5 INHIBITORS AND MODULATORS
WO2021026672A1 (en) 2019-08-09 2021-02-18 Novartis Ag Heterocyclic wdr5 inhibitors as anti-cancer compounds

Also Published As

Publication number Publication date
EP3423451A1 (en) 2019-01-09
DK3423451T3 (da) 2022-11-28
IL261472B (en) 2022-01-01
JP2022071046A (ja) 2022-05-13
CN109195965A (zh) 2019-01-11
AU2017226004B2 (en) 2021-07-22
CL2018002505A1 (es) 2019-01-04
JP2024102151A (ja) 2024-07-30
ECSP18073726A (es) 2018-11-30
WO2017147700A1 (en) 2017-09-08
US11319299B2 (en) 2022-05-03
JP2019512482A (ja) 2019-05-16
BR112018067392A2 (pt) 2019-01-02
IL261472A (en) 2018-10-31
KR20180120720A (ko) 2018-11-06
US20230219926A1 (en) 2023-07-13
EP3423451B1 (en) 2022-08-17
EA038109B1 (ru) 2021-07-07
MX2018010374A (es) 2019-03-28
US12264147B2 (en) 2025-04-01
US20190112290A1 (en) 2019-04-18
EP3423451A4 (en) 2019-09-04
CN109195965B (zh) 2022-07-26
CA3015406A1 (en) 2017-09-08
ZA201805879B (en) 2021-04-28
EA201891974A1 (ru) 2019-04-30
JP7624690B2 (ja) 2025-01-31
AU2017226004A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
ECSP18073726A (es) Inhibidores del enlace proteína-proteína de wdr5
ECSP24026455A (es) Compuestos de pirrolotriazina como inhibidores de tam
ECSP17070706A (es) Inhibidores de bromodominio
MX2020007383A (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47.
CL2018002516A1 (es) Inhibidores de mcl-1 indólicos sustituidos.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
CR20160229A (es) Inhibidires de bromodominio
MX385138B (es) Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes.
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
ECSP19026702A (es) Compuestos novedosos para el tratamiento de enfermedades parasitarias
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
ECSP19051377A (es) Derivados de pirrolotriazina como inhibidor de cinasas